metronidazole has been researched along with lansoprazole in 184 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 53 (28.80) | 18.2507 |
| 2000's | 76 (41.30) | 29.6817 |
| 2010's | 53 (28.80) | 24.3611 |
| 2020's | 2 (1.09) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Castillo, R; Hernández-Campos, A; Hernández-Luis, F; Pérez-Villanueva, J; Romo-Mancillas, A; Yépez-Mulia, L | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Bala, V; Chhonker, YS | 1 |
| Johnson, CD; Ozmen, MM | 1 |
| Bell, JM; Lambert, JR; Midolo, PD; Turnidge, JD | 1 |
| Cammarota, G; Fedeli, G; Gasbarrini, G; Montalto, M; Papa, A; Tursi, A | 1 |
| Baniukiewicz, A; Bielański, W; Gabryelewicz, A; Hahn, EG; Jedynak, M; Konturek, PC; Konturek, SJ; Kwiecień, N; Sito, E | 1 |
| Jaup, BH; Norrby, A | 1 |
| de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ | 1 |
| Herman, R; Konturek, JW; Konturek, SJ; Lorens, K; Tabor, S; Thor, P | 1 |
| Kawano, S; Murakami, M; Saita, H; Tsuji, S | 1 |
| Ishino, Y; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yamamoto, H; Yoshida, Y | 1 |
| Baron, JH; Gabe, SM; Harris, AW; Karim, QN; Langworthy, H; Misiewicz, JJ; Pryce, DI; Walker, MM | 1 |
| Bock, H; Mares, A | 1 |
| Kajiwara, M; Kawada, H; Kidaira, K; Kimura, K; Nishifuku, K; Sato, K; Sohara, H; Taniguchi, Y; Wang, XM | 1 |
| Alvisi, V; Caselli, M; Gasbarrini, G; Gaudenzi, P; Luzzi, I; Ruina, M; Sartori, S; Trevisani, L; Tursi, A | 1 |
| de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ; van Unnik, AJ | 1 |
| Adachi, H; Ahmed, T; Hori, T; Matsubara, T; Nakahara, A; Sumazaki, R; Takita, H; Yamada, M | 1 |
| Akahane, T; Akamatsu, T; Gotoh, A; Katsuyama, T; Kawakami, Y; Kiyosawa, K; Shimizu, T | 1 |
| Bargiggia, S; Bianchi Porro, G; Lazzaroni, M | 1 |
| Kimura, M; Seki, H; Urakami, Y | 1 |
| Ikemura, N; Imoto, I; Misaki, M; Nakao, K; Shibata, T; Taguchi, Y; Takaji, S; Yamauchi, K; Yamazaki, N | 1 |
| Barnett, JL; Chey, WD; DelValle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Scheiman, JM | 1 |
| el-Zimaity, HM; Graham, DP; Graham, DY; Hoffman, J; Osato, M | 1 |
| Arora, A; Graham, D; Haber, M; Harford, W; Lanza, F; Rose, P; Siepman, N; Weissfeld, A | 1 |
| Haber, M; Kidd, S; Krause, R; Rose, P; Sahba, B; Schwartz, H; Siepman, N; Weissfeld, A | 1 |
| Malfertheiner, P; Mégraud, F | 1 |
| de Boer, WA; Driessen, WM; Lai, JY; Schneeberger, PM; van de Wouw, BA; van Etten, RJ | 1 |
| Ido, K; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Seki, M; Takimoto, T; Taniguchi, Y; Yoshida, Y | 1 |
| Akamatsu, T; Gotoh, A; Katsuyama, T; Kawakami, Y | 1 |
| Fennerty, MB | 1 |
| Bardhan, KD; Cooper, BT; Dixon, MF; Harris, AW; Kerr, GD; Langworthy, H; Levi, S; Misiewicz, JJ; O'Morain, C; Piper, D | 2 |
| El-Zimaity, HM; Graham, DY; Kim, JG; Osato, MS; Perng, CL | 1 |
| Collins, BJ; Coombs, GW; Forbes, GM; McCullough, CA; Robins, PD | 1 |
| Cunnane, K; Kelly, S; Laundon, J; McLoughlin, R; O'Connor, HJ | 1 |
| de Boer, WA; Schneeberger, PM; van Etten, RJ | 1 |
| Barbet, JP; Benhamou, PH; Bergeret, M; Dupont, C; Gendrel, D; Kalach, N; Raymond, J | 1 |
| de Boer, SY; Siem, TH | 1 |
| Ahuja, V; Bal, C; Dhar, A; Sharma, MP | 1 |
| Benhamou, PH; Bergeret, M; Dupont, C; Gendrel, D; Kalach, N; Raymond, J; Senouci, L | 1 |
| Coremans, A; de Boer, WA; Schneeberger, PM; van Etten, RJ | 1 |
| Bolin, TD; Engelman, JL; Korman, MG; Nicholson, FB | 1 |
| Bock, H; Domschke, W; Heep, M; Kirchner, T; Lehn, N; Pohle, T; Stoll, R | 1 |
| Boixeda, D; Gisbert, JP; Martín de Argila, C | 1 |
| Iwasaki, A | 1 |
| Harasawa, S; Kouda, K; Kurumada, T; Miwa, T; Shirai, T; Tada, U; Takagi, A; Wada, T; Watanabe, S | 1 |
| Kihira, K; Kimura, K; Kumakura, Y; Sato, K; Sugano, K; Yoshida, Y | 1 |
| Axon, AT; Everett, S; Langworthy, H; Mapstone, NP; Moayyedi, P; Neville, PM; Tompkins, D | 1 |
| Bozzola, L; Di Mario, F; Fortunato, A; Franceschi, M; Leandro, G; Meli, S; Pilotto, A; Rassu, M; Scagnelli, M; Soffiati, G; Valerio, G | 1 |
| Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M | 1 |
| Bravo, LE; Correa, P; DeLany, JP; Mera, R; Realpe, JL | 1 |
| de Boer, WA; de Grauw, WJ; Lai, JY | 1 |
| Ducóns, JA; Ferrero, M; García Cabezudo, J; Gomollón, F; Guirao, R; Montoro, M; Simón, MA | 1 |
| Asaka, M; Ishizuka, J; Kagaya, H; Katagiri, M; Kato, M; Komatsu, Y; Kudo, M; Kudo, T; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H; Toyota, J | 1 |
| Hoshiya, S; Ishida, H; Itoh, T; Ninomiya, H; Saito, S; Shingaki, M; Takahashi, S; Tanaka, A; Tokunaga, K; Watanabe, K | 1 |
| De Boer, WA; Jansen, JB; Schneeberger, PM; Van De Wouw, BA; Van Etten, RJ; Van Oijen, AH | 1 |
| Carpio, RE; Fock, KM; Ho, J; Hu, FL; Hu, PJ; Huang, NX; Kachintorn, U; Kullavanijaya, P; Lam, SK; Lesmana, L; Li, YY; Manan, C; Perez, JY; Phornphutkul, K; Qian, SC; Wong, BC; Xiao, SD | 1 |
| Akamatsu, T; Furihata, K; Miyabayashi, H; Shimizu, T; Ueno, I | 1 |
| de Boer, WA; Nouhan, N; Plaisier, AP; Quint, WG; Schneeberger, PM; van Doorn, LJ | 1 |
| Brousal, A; Kearney, DJ | 1 |
| Begum, S; Endo, H; Kawamata, H; Sano, T; Urakami, Y | 1 |
| Azuma, T; Ito, S; Ito, Y; Kato, T; Kuriyama, M; Miyaji, H; Suto, H; Yamazaki, Y | 1 |
| Ammon, S; Kees, F; Klotz, U; Treiber, G | 1 |
| Imai, T; Konno, M; Muraoka, S; Takahashi, M | 1 |
| Buzás György, M; Illyés, G; Székely, E; Széles, I | 1 |
| Huang, AH; Huang, CC; Lin, XZ; Sheu, BS; Wu, JJ; Yang, HB | 1 |
| Botta, F; Chiarbonello, B; Fasoli, A; Giannini, E; Lantieri, PB; Malfatti, F; Risso, D; Romagnoli, P; Savarino, V; Testa, R | 1 |
| Begum, S; Endo, H; Kawamata, H; Oki, Y; Sano, T; Urakami, Y | 1 |
| Ohkusa, T; Watanabe, M | 1 |
| Avidan, B; Bar-Meir, S; Keller, N; Melzer, E | 1 |
| Chan, CK; Chu, KM; Fung, FM; Hu, FL; Hu, WH; Hui, WM; Kung, NN; Lai, KC; Lam, SK; Lau, GK; Liu, XG; Wang, WH; Wong, BC; Wong, WM; Yuen, MF | 1 |
| Hojo, M; Miwa, H; Nagahara, A; Ohkura, R; Sato, K; Sato, N; Yamada, T | 1 |
| Bateson, MC | 1 |
| Burm, M; Faigel, D; Fennerty, MB; Kelly, C; Magaret, N; Peterson, W | 1 |
| Hsu, CT; Kuo, CF; Wang, CS; Wang, TH; Yang, JC; Yang, KC | 1 |
| Ammon, S; Klotz, U; Treiber, G; van Doorn, LJ; Walker, S; Wittig, J | 1 |
| Fujioka, T; Kodama, M; Murakami, K; Nasu, M; Okimoto, T; Sato, R | 1 |
| Alampi, G; Bazzoli, F; Berretti, D; De Luca, L; Di Pietro, C; Fossi, S; Morelli, P; Nicolini, G; Pozzato, P; Ricciardiello, L; Roda, E; Zagari, RM | 1 |
| Chang, CS; Chen, GH; Lai, CH; Poon, SK; Su, J; Wang, WC; Yang, CC | 1 |
| Haapiainen, R; Härkönen, M; Kokkola, A; Kosunen, TU; Puolakkainen, P; Rautelin, H; Sipponen, P | 1 |
| Barbier, C; Benhamou, PH; Bergeret, M; Dupont, C; Gottrand, F; Husson, MO; Kalach, N; Raymond, J | 1 |
| Satoh, K | 1 |
| Ohkusa, T; Sato, N | 1 |
| Miwa, H; Miyazaki, A; Nagahara, A; Sato, N | 1 |
| Inoue, K; Sugano, K | 1 |
| Kiriyama, Y; Koizumi, K; Kuwayama, H; Ohara, T; Suga, M; Suzuki, K; Takahashi, M; Takata, H | 1 |
| Isomoto, H; Kohno, S | 1 |
| Calvet, X; Gisbert, JP; Vallve, M; Vergara, M | 1 |
| Akamatsu, T; Gotoh, A; Ikeno, T; Ishida, K; Kaneko, T; Katsuyama, T; Kawakami, Y; Kiyosawa, K; Ota, H; Shimizu, T; Shimodaira, K; Sugiyama, A | 1 |
| Chuang, CH; Huang, AH; Sheu, BS; Wu, JJ; Yang, HB | 1 |
| Rai, R; Rai, S | 1 |
| Sano, T; Urakami, Y | 1 |
| Cisneros, G; Gurney, M; Jarjoura, D; Lara, LF; Moauro, B; Polen, A; Rutecki, G; Van Ness, M; Whittier, F | 1 |
| Ahuja, V; Bal, C; Bhatia, V; Das, B; Sharma, MP | 1 |
| Granström, M; Hoang, TT; Nilsson, LE; Phuncarg, DC; Sörberg, M; Wheeldon, TU | 1 |
| de Boer, WA; Jansen, JB; Janssen, MJ; Laheij, RJ | 1 |
| Fukuda, S; Fukushi, M; Mikami, T; Munakata, A; Shimoyama, T | 1 |
| Iinuma, K; Kato, S; Konno, M; Maisawa, S; Nakayama, Y; Shimizu, T; Tajiri, H; Toyoda, S; Yoshimura, N | 1 |
| Hirashima, N; Ito, K; Kato, A; Kato, H; Kondo, H; Matsunaga, S; Nukaya, H; Sakakibara, K; Sakamoto, T; Tanaka, Y | 1 |
| Asaoka, D; Hojo, M; Iijima, K; Kawabe, M; Kurosawa, A; Miwa, H; Miyazaki, A; Nagahara, A; Ohkusa, T; Sato, N; Terai, T | 1 |
| Bellotti, M; Botta, F; Chiarbonello, B; Cotelessa, T; Emanuela, T; Fumagalli, A; Giannini, E; Malfatti, F; Milazzo, S; Podestà, E; Polegato, S; Testa, R | 1 |
| Färkkilä, MA; Heikkinen, MT; Koivisto, TT; Koskenpato, JP; Rautelin, HI; Voutilainen, ME | 1 |
| Abasiyanik, MF; Huten, O; Salih, BA; Sander, E; Saribasak, H | 1 |
| Baggett, HC; Bruce, MG; Dunaway, E; Gessner, BD; Gold, BD; Muth, PT; Parkinson, AJ | 1 |
| Asaka, M | 1 |
| Nagahara, A; Sato, N | 1 |
| Furuta, T; Nakamura, A; Shirai, N; Sugimoto, M | 1 |
| Bray, R; Hiratsuka, H; Hiratsuka, T; Kimura, K; Suzuki, T; Tamura, K | 1 |
| Fujishiro, M; Kobayashi, K; Oka, M; Omata, M | 1 |
| Asaka, M; Kato, M; Nakagawa, M; Nakagawa, S; Shimizu, Y | 1 |
| Konno, M | 1 |
| Katoh, H; Kuwano, H; Miyazaki, T; Tsukada, K | 1 |
| Chan, AO; Chan, CK; Chu, KM; Fung, FM; Gu, Q; Lai, KC; Tong, TS; Wong, BC; Wong, WM; Yee, YK | 1 |
| Classen, M; Li, J; Lin, SR; Liu, WD; Ma, JL; Pan, KF; Shen, L; Xiao, SD; You, WC; Zhang, L | 1 |
| Fujioka, T; Inoue, K; Kodama, M; Miyajima, H; Murakami, K; Okimoto, T; Ono, M; Otsu, S; Sato, R; Watanabe, K | 1 |
| Apikoglu-Rabus, S; Besisik, F; Dulger, G; Izzettin, FV; Sancar, M; Tozun, N | 1 |
| Kast, RE | 1 |
| Fukuda, S; Fukushi, M; Munakata, A; Nakasato, F; Shimoyama, T; Tanaka, M | 1 |
| Aslan, M; Bagci, S; Erdil, A; Gunhan, O; Ozel, AM; Uygun, A; Yesilova, Z; Yildiz, O | 1 |
| Chung, SJ; Hwang, JH; Jung, HC; Jung, SH; Kim, JW; Kim, N; Lee, DH; Lee, KH; Park, YS; Song, IS | 1 |
| Bagci, S; Ilgan, S; Kadayifci, A; Safali, M; Uygun, A | 1 |
| Fujioka, T; Kodama, M; Murakami, K; Okimoto, T; Sato, R; Watanabe, K | 2 |
| Hirata, Y; Kawabe, T; Maeda, S; Mitsuno, Y; Ogura, K; Ohmae, T; Okamoto, M; Omata, M; Shibata, W; Watabe, H; Yamaji, Y; Yanai, A; Yoshida, H | 1 |
| Ching, SS; Jenkinson, LR; Sabanathan, S | 1 |
| Bengtsson, C; Granström, M; Hoang, TT; Nguyen, GK; Nguyen, TV; Phung, DC; Sörberg, M | 1 |
| Abdullahi, M; Annibale, B; Capoccia, D; Leonetti, F; Marcheggiano, A; Osborn, J; Severi, C; Tari, R; Vannella, L | 1 |
| Balkarli, A; Baştürk, A; Cerçi, S; Senol, A; Songür, Y | 1 |
| Mahachai, V; Sirimontaporn, N; Thong-Ngam, D; Tumwasorn, S | 1 |
| Angelini, R; Pontone, P; Pontone, S; Standoli, M | 1 |
| Kilic, ZM; Nadir, I; Ozin, Y; Sezgin, O; Yonem, O | 1 |
| Asaka, M; Furukawa, K; Furuta, T; Inaba, T; Ishii, N; Kamoshida, T; Kato, M; Konda, Y; Nomura, H; Sasaki, M; Shirai, T; Sugimoto, M; Tomita, T | 1 |
| Ince, AT; Kesici, B; Polat, Z; Saglam, M; Toros, AB; Uygun, A | 1 |
| Goto, Y; Hamajima, N; Inoue, S; Kamiya, Y; Kawai, S; Kondo, T; Kurata, M; Tamura, T | 1 |
| Anderson, GL; Baker, LH; Bravo, LE; Chey, WD; Correa, P; Crowley, JJ; Dominguez, RL; Ferreccio, C; Goodman, GE; Greenberg, ER; Herrero, R; Lazcano-Ponce, EC; Martínez, ME; Meza-Montenegro, MM; Morgan, DR; Peña, EM; Peña, R; Salazar-Martínez, E; Torres, J; Valdivieso, M | 1 |
| Francesconi, CF; Mazzoleni, LE; Sander, GB | 1 |
| Chang, LL; Chen, YH; Huang, YK; Kuo, CH; Kuo, FC; Lee, YC; Wang, SS; Wang, TH; Wang, WM; Wu, DC; Wu, MC | 1 |
| Choi, JH; Chun, HJ; Hyun, JJ; Jung, SW; Kim, SY; Koo, JS; Lee, SW; Park, JJ; Yim, HJ | 1 |
| Chung, JW; Hahm, KB; Jeong, JY; Jung, YK; Kim, JH; Kim, YJ; Kwon, KA; Lee, JJ; Lee, SM; Yun, SC | 1 |
| Chang, CY; Chang, WH; Chen, CC; Chen, MJ; Fang, YJ; Hsu, SJ; Hsu, YC; Lee, JY; Lee, YC; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Tseng, CH; Tseng, PH; Wang, HP; Wu, MS; Yang, UC | 1 |
| Anderson, GL; Baker, LH; Bravo, LE; Chey, WD; Correa, P; Crowley, JJ; Dominguez, RL; Ferreccio, C; Goodman, GE; Greenberg, ER; Herrero, R; Lazcano-Ponce, EC; Martínez, ME; Meza-Montenegro, MM; Morgan, DR; Peña, EM; Peña, R; Salazar-Martínez, E; Sexton, R; Torres, J; Valdivieso, M | 1 |
| Malfertheiner, P | 1 |
| Botero, ML; Cárdenas, A; Forero, JD; Rey, M; Sierra, F | 1 |
| Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A | 1 |
| Benzer, E; Bilir, G; Gokcan, H; Onal, IK; Oztas, E | 1 |
| Kato, M | 1 |
| Akdoğan, RA; Bedir, R; Copur, A; Rakici, H; Yilmaz, A | 1 |
| Cho, KB; Ha, CY; Heo, J; Jang, BI; Jeon, SW; Jung, JT; Kim, ES; Kim, EY; Kim, HJ; Kwon, JG; Lee, DW; Lee, SH; Park, KS; Seo, HE | 1 |
| Akyon, Y; Bayrak, A; Celikel, C; Ertem, D; Kutluk, G; Tutar, E; Volkan, B | 1 |
| Sakallioglu, O | 1 |
| Chung, JW; Kim, KO; Kim, SY; Kim, YJ; Kwon, KA; Park, DK | 1 |
| Cao, Z; Chen, Q; Liang, X; Liao, J; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
| Hauser, G; JajacKnez, A; Salkic, N; Stimac, D; Vukelic, K | 1 |
| Chen, Q; Graham, DY; Liang, X; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
| Bair, MJ; Chang, CC; Chang, CY; Chang, WH; Chen, CC; Chen, MJ; Fang, YJ; Hsieh, CF; Hsu, YC; Lee, JY; Lee, YC; Lin, JT; Liou, JM; Liou, TC; Liu, TY; Luo, JC; Shun, CT; Tsao, FY; Tseng, CH; Wu, JY; Wu, MS; Yang, TH | 1 |
| Ahmed, MR; Mel-Hennawi, D | 1 |
| Bair, MJ; Chang, CC; Chang, CY; Chang, WH; Chen, CC; Chen, CY; Chen, MJ; Chen, PY; Fang, YJ; Hsu, WF; Hung, HW; Lee, JY; Lee, YC; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Tseng, CH; Wu, JY; Wu, MS; Yang, TH | 1 |
| Niv, Y | 1 |
| Bakshi, SS | 1 |
| Asaka, M; Funao, N; Murakami, K; Nishimura, A; Sakurai, Y; Shiino, M | 1 |
| Fukayama, M; Hayakawa, Y; Hirata, Y; Koike, K; Niikura, R; Shichijo, S; Ushiku, T; Yamada, A | 1 |
| Ahmed, MR | 1 |
| Ida, A; Miyaki, A; Miyauchi, T; Yamaguchi, K | 1 |
| Chen, Q; Fu, Q; Liang, X; Liu, W; Lu, H; Xiao, S; Zhang, W | 1 |
| Bair, MJ; Chang, CC; Chang, CY; Chen, CC; Chen, CY; Chen, MJ; Chen, PY; Chen, YN; El-Omar, EM; Fang, YJ; Hsu, WF; Hsu, YC; Hu, WH; Lee, JY; Lee, YC; Lin, JT; Liou, JM; Luo, JC; Sheu, BS; Shun, CT; Tseng, CH; Wu, JY; Wu, MS; Yang, TH | 1 |
| Akay, S; Akpinar, Z; Unsal, B | 1 |
| Choi, IJ; Kim, BJ; Kim, JG; Kim, JI; Kim, JJ; Kim, SG; Lee, H; Lee, YC | 1 |
| Robotis, J; Rokkas, T; Tsiodras, S | 1 |
| Irie, K; Kaneko, H; Kondo, M; Maeda, S; Sasaki, T; Shibata, W; Sue, S | 1 |
| Chu, CH; Liao, PH; Lin, YC; Liou, TC; Shih, SC | 1 |
| Baik, GH; Choi, IJ; Jeon, SW; Kim, BJ; Kim, GH; Kim, HS; Kim, HU; Kim, J; Kim, JG; Kim, JI; Kim, JJ; Kim, SG; Kim, SW; Lee, DH; Lee, H; Lee, J; Lee, JY; Lee, YC; Park, MI; Sung, JK; Yoon, SM | 1 |
| Bair, MJ; Chang, CM; Chang, CY; Chen, CC; Chen, CY; Chen, MJ; Chen, PY; Chen, YN; Chuang, EY; El-Omar, EM; Fang, YJ; Hsu, WF; Hsu, YC; Lee, JY; Lin, JT; Liou, JM; Lu, TP; Luo, JC; Wu, JY; Wu, MS; Yang, TH | 1 |
| Fukuda, K; Fukuda, M; Hirashita, Y; Kawahara, Y; Kodama, M; Kudo, Y; Matsunari, O; Mizukami, K; Murakami, K; Ogawa, R; Okamoto, K; Okimoto, T; Wada, Y | 1 |
| Hassib, ST; Mostafa, EA; Sharf, MG; Taha, EA | 1 |
21 review(s) available for metronidazole and lansoprazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Recent developments in anti-Trichomonas research: An update review.
Topics: Antiparasitic Agents; Biological Products; Dose-Response Relationship, Drug; Humans; Molecular Structure; Parasitic Sensitivity Tests; Structure-Activity Relationship; Trichomonas; Trichomonas Infections | 2018 |
[Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors | 1999 |
[A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Mixed Function Oxygenases; Omeprazole; Patient Compliance; Polymorphism, Genetic; Proton Pump Inhibitors; Treatment Failure | 2001 |
[New triple therapy for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors | 2002 |
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tetracycline | 2002 |
[Effect of PPI/AM re-treatment regimen for the patients with Helicobacter pylori infection after failure of first line eradication therapy by PPI/AC regimens].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Treatment Failure; Treatment Outcome | 2002 |
[Eradication therapy for clarithromycin-resistant and metronidazole-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Treatment Failure | 2002 |
[Polaprezinc].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Ulcer Agents; Carnosine; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Bacterial; Drug Synergism; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Organometallic Compounds; Peptic Ulcer; Urease; Zinc Compounds | 2002 |
[Helicobacter heilmannii-associated gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter heilmannii; Helicobacter Infections; Humans; Lansoprazole; Metronidazole; Omeprazole; Organometallic Compounds; Tetracycline | 2002 |
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Rabeprazole; Sulfoxides; Treatment Outcome | 2002 |
[Evaluation of the efficacy of an Helicobacter pylori eradication treatment for idiopathic thrombocytopenic purpura patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Purpura, Thrombocytopenic, Idiopathic | 2004 |
[Guidelines in the management of H. pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Metronidazole; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors | 2005 |
[Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Treatment Outcome | 2005 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2005 |
[Comparison between one-week and two-week regimens of new triple therapy in H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Time Factors; Treatment Outcome | 2005 |
[Investigation about 3rd line eradication of H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ampicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic; Proton Pump Inhibitors; Rabeprazole; Treatment Failure | 2005 |
[Helicobacter pylori eradication therapy for children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Enzyme Inhibitors; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Treatment Outcome | 2005 |
[Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dialysis; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Kidney Failure, Chronic; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors | 2005 |
[Expanded indication of National Health Insurance for H. pylori associated gastritis].
Topics: Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Metronidazole; National Health Programs; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2014 |
Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Proton Pump Inhibitors; Ranitidine; Tetracycline | 2016 |
103 trial(s) available for metronidazole and lansoprazole
| Article | Year |
|---|---|
Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Time Factors | 1995 |
One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Acidity Determination; Gastric Mucosa; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Tinidazole | 1996 |
Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Tetracycline | 1996 |
4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Premedication; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Time Factors | 1996 |
Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Microbial; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Patient Compliance | 1996 |
Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Biopsy; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Duodenal Ulcer; Endoscopy, Digestive System; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Stomach Ulcer; Treatment Outcome | 1997 |
One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Diarrhea; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Tetracycline | 1997 |
Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Costs and Cost Analysis; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Proton Pump Inhibitors; Ranitidine; Single-Blind Method; Time Factors | 1997 |
Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Microbial; Dyspepsia; Evaluation Studies as Topic; Feces; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Medical Records; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Peptic Ulcer; Proton Pump Inhibitors; Salicylates; Taste Disorders | 1997 |
Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Salicylates; Smoking; Tetracycline; Tetracyclines | 1997 |
Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diarrhea; Double-Blind Method; Drug Eruptions; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Hypertension; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prevalence; Proton Pump Inhibitors; Research Design; Treatment Outcome | 1996 |
Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Clarithromycin; Diarrhea; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Safety; Taste Disorders; Treatment Outcome | 1996 |
Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Bacterial Proteins; Breath Tests; Carbon Isotopes; Drug Resistance, Microbial; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Tetracycline; Treatment Outcome; Urea; Urease | 1996 |
The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole | 1997 |
Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Placebos; Proton Pump Inhibitors; Ranitidine; Tetracycline | 1998 |
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Single-Blind Method | 1997 |
Short duration therapy for Helicobacter pylori in Western Australia: the impact of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Penicillins; Tetracycline; Western Australia | 1998 |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Diarrhea; Drug Therapy, Combination; Endoscopes; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Nausea; Omeprazole; Patient Compliance; Peptic Ulcer; Prospective Studies; Taste Disorders; Time Factors; Treatment Outcome | 1998 |
Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Netherlands; Omeprazole; Organometallic Compounds; Tetracycline; Treatment Outcome | 1998 |
Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Developing Countries; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Pefloxacin; Proton Pump Inhibitors | 1998 |
Spiramycin as an alternative to amoxicillin treatment associated with lansoprazole/metronidazole for Helicobacter pylori infection in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Drug Therapy, Combination; Gastrointestinal Agents; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Spiramycin | 1998 |
Two-day 'weekend' lansoprazole-quadruple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Biopsy; Clinical Protocols; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Tetracycline | 1998 |
Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Combined Modality Therapy; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors; Treatment Outcome | 1998 |
Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Tetracycline; Treatment Outcome | 1998 |
Eradication of Helicobacter pylori with lansoprazole, roxithromycin and metronidazole--an open pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Drug Resistance, Microbial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole; Pilot Projects; Polypharmacy; Roxithromycin | 1998 |
[Previous treatment with omeprazole and H. pylori: does it diminish the eradication efficacy of the "new" triple therapies of one week's duration?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Odds Ratio; Omeprazole; Penicillins; Prognosis; Prospective Studies; Time Factors | 1998 |
[Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Evaluation; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Tetracycline; Treatment Outcome | 1999 |
[Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine; Treatment Outcome | 1999 |
The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Single-Blind Method; Treatment Outcome | 1999 |
Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Antibodies, Bacterial; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Treatment Outcome | 1999 |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Ranitidine; Treatment Outcome | 1999 |
Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Proton Pump Inhibitors; Salicylates; Treatment Outcome | 1999 |
Helicobacter treatment with quadruple therapy in primary health care for patients with a history of ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Quality of Life; Surveys and Questionnaires; Tetracycline; Time Factors; Treatment Outcome | 1999 |
Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 1999 |
Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Carbon Isotopes; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Time Factors; Treatment Outcome; Urea | 1999 |
Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; Enzyme Inhibitors; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Tetracycline | 2000 |
Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Asia; Breath Tests; Clarithromycin; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Risk Factors; Urea | 2000 |
Influence of oral Helicobacter pylori on the success of eradication therapy against gastric Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Dental Plaque; DNA, Bacterial; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Mouth Mucosa; Omeprazole; Polymerase Chain Reaction; Saliva; Sensitivity and Specificity; Treatment Outcome; Urease | 2000 |
Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Regression Analysis; Tetracycline; Treatment Outcome | 2000 |
Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Liver Cirrhosis; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer | 2000 |
[Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Treatment Outcome | 2000 |
Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole; Prospective Studies; Treatment Outcome | 2000 |
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aminopyrine; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Carbon Radioisotopes; Clarithromycin; Cytochrome P-450 Enzyme Inhibitors; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Sulfoxides | 2000 |
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Organometallic Compounds; Patient Selection; Penicillins; Peptic Ulcer; Time Factors; Treatment Failure | 2001 |
Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Treatment Outcome | 2001 |
Quadruple therapy for symptomatic spontaneous duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Tetracycline | 2001 |
A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors | 2001 |
A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies | 1999 |
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine; Regression Analysis; Treatment Outcome | 2002 |
Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Costs; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Treatment Outcome | 2002 |
Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Taiwan | 2002 |
Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Pronase; Treatment Outcome | 2002 |
Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Ascorbic Acid; Dietary Supplements; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Inflammation; Lansoprazole; Male; Metronidazole; Omeprazole; Severity of Illness Index; Stomach Diseases; Treatment Outcome; Vitamin E | 2002 |
One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates; Severity of Illness Index; Treatment Outcome | 2003 |
Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans; India; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Peptic Ulcer; Prospective Studies; Tinidazole; Treatment Outcome; Wound Healing | 2004 |
The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Tinidazole; Treatment Outcome | 2004 |
The influence of pretreatment on cure rates of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Tetracycline | 2004 |
Effects of the association of lansoprazole, clarithromycin and metronidazole for helicobacter Pylori eradication therapy, measured by the 13C Aminopyrine breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Aminopyrine; Breath Tests; Carbon Isotopes; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Sex Characteristics | 2005 |
First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Multivariate Analysis; Omeprazole; Ranitidine; Risk Factors | 2005 |
A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Atrophy; Female; Follow-Up Studies; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Intestines; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Omeprazole; Severity of Illness Index; Stomach; Treatment Outcome | 2005 |
A randomized trial of triple therapy for pediatric Helicobacter pylori infection and risk factors for treatment failure in a population with a high prevalence of infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Child; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole; Prevalence; Prospective Studies; Risk Factors; Treatment Failure | 2005 |
[PPI plus bismuth-based quintuple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Minocycline; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Treatment Outcome | 2005 |
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Organometallic Compounds; Tetracycline; Treatment Outcome | 2006 |
Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Pilot Projects; Prospective Studies; Rural Population | 2006 |
Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Famotidine; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Middle Aged; Proton Pump Inhibitors; Proton Pumps; Treatment Failure | 2006 |
Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Melena; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Prospective Studies; Ranitidine; Taste Disorders; Time Factors; Treatment Outcome | 2006 |
Duration of the metronidazole-containing regimen for eradication of Helicobacter pylori infection in northern Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Time Factors | 2006 |
Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Organometallic Compounds; Proton Pump Inhibitors; Tetracycline; Treatment Failure; Treatment Outcome; Turkey | 2008 |
The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Middle Aged; Single-Blind Method; Statistics, Nonparametric; Tetracycline; Treatment Outcome | 2007 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Retreatment; Treatment Outcome | 2008 |
Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Hospitals, General; Hospitals, Rural; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Organometallic Compounds; Patient Compliance; Prospective Studies; Tetracycline; Treatment Outcome | 2008 |
Evaluation of two triple-therapy regimens with metronidazole or clarithromycin for the eradication of H. pylori infection in Vietnamese children: a randomized, double-blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Antigens, Bacterial; Child; Child, Preschool; Clarithromycin; Double-Blind Method; Feces; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Stomach; Vietnam | 2008 |
High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Organometallic Compounds; Proton Pump Inhibitors; Young Adult | 2009 |
Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Tetracycline; Treatment Outcome; Young Adult | 2009 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Treatment Outcome | 2010 |
Comparison of two different treatment protocols in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Tetracycline; Turkey | 2011 |
Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Failure | 2011 |
A new modified concomitant therapy for Helicobacter pylori eradication in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Treatment Outcome; Young Adult | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Latin America; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Time Factors; Treatment Outcome; Urea | 2011 |
Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Outcome | 2012 |
Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Algorithms; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Middle Aged; Prospective Studies; Treatment Outcome | 2013 |
Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Chi-Square Distribution; Clarithromycin; Confidence Intervals; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Lansoprazole; Male; Metronidazole; Middle Aged; Patient Compliance; Republic of Korea; Urea | 2012 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Ofloxacin | 2013 |
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Humans; Lansoprazole; Latin America; Male; Medication Adherence; Metronidazole; Middle Aged; Primary Prevention; Recurrence; Risk; Stomach Neoplasms; Young Adult | 2013 |
[Is sequential eradication of Helicobacter pylori effective? Sequential treatment more effective than triple therapy in patients with clarithromycin resistance].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Peptic Ulcer; Stomach Neoplasms; Taiwan | 2013 |
Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Middle Aged; Moxifloxacin; Proton Pump Inhibitors; Treatment Outcome; Young Adult | 2014 |
A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Logistic Models; Male; Metronidazole; Middle Aged; Multivariate Analysis; Prospective Studies; Republic of Korea; Time Factors; Treatment Outcome | 2014 |
Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains?
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Child; Child, Preschool; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Treatment Outcome | 2014 |
Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Biopsy, Needle; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Immunohistochemistry; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bifidobacterium; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lacticaseibacillus rhamnosus; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Pantoprazole; Placebos; Probiotics; Prospective Studies; Proton Pump Inhibitors; Surveys and Questionnaires; Treatment Outcome | 2015 |
Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Young Adult | 2015 |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of
Topics: Adult; Ambulatory Care; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hospitalization; Humans; Lansoprazole; Male; Metronidazole; Proton Pump Inhibitors; Treatment Outcome | 2016 |
Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion.
Topics: Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Case-Control Studies; Child; Child, Preschool; Chronic Disease; Clarithromycin; Clavulanic Acid; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Otitis Media with Effusion; Proton Pump Inhibitors; Treatment Outcome | 2015 |
Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Levofloxacin; Male; Metronidazole; Middle Aged; Stomach Diseases; Treatment Outcome | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Pyrroles; Sulfonamides; Treatment Outcome | 2016 |
Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Middle Aged; Peptic Ulcer; Proton Pump Inhibitors; Tetracycline; Treatment Failure; Treatment Outcome; Young Adult | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Organometallic Compounds; Proton Pump Inhibitors; Taiwan; Tetracycline; Urea | 2016 |
Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors | 2017 |
Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial.
Topics: Amoxicillin; Clarithromycin; Clinical Protocols; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Sample Size | 2017 |
Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Gastritis; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Pyrroles; Rabeprazole; Sulfonamides; Treatment Failure; Treatment Outcome | 2019 |
Intraluminal therapy for Helicobacter pylori infection.
Topics: Acetylcysteine; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Expectorants; Female; Gastric Acid; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Metronidazole; Middle Aged; Powders; Prospective Studies; Proton Pump Inhibitors; Remission Induction; Therapeutic Irrigation; Time Factors; Treatment Outcome; Young Adult | 2019 |
Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Medication Adherence; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Republic of Korea; Treatment Outcome | 2019 |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Body Mass Index; Clarithromycin; Disease Eradication; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Escherichia coli; Female; Follow-Up Studies; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metabolic Syndrome; Metronidazole; Middle Aged; Organometallic Compounds; Prevalence; Tetracycline | 2019 |
60 other study(ies) available for metronidazole and lansoprazole
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Antiprotozoal activity of proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antiprotozoal Agents; Drug Design; Entamoeba histolytica; Giardia lamblia; Humans; Lansoprazole; Omeprazole; Pantoprazole; Parasitic Diseases; Proton Pump Inhibitors; Rabeprazole; Trichomonas vaginalis | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Air; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Helicobacter pylori; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Oxygen; Proton Pump Inhibitors | 1996 |
Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole | 1996 |
Dysfunction in gastric myoelectric and motor activity in Helicobacter pylori positive gastritis patients with non-ulcer dyspesia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Electromyography; Female; Gastric Emptying; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Myoelectric Complex, Migrating; Omeprazole | 1996 |
Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Proton Pump Inhibitors; Stomach Ulcer; Tinidazole | 1996 |
Endoscopic topical therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Topical; Amoxicillin; Antacids; Anti-Ulcer Agents; Bismuth; Drug Combinations; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Instillation, Drug; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Pronase | 1996 |
[Good results with Helicobacter pylori eradication for treatment of non-ulcer dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Roxithromycin; Treatment Outcome | 1996 |
[Time course of disappearance of Helicobacter pylori after topical therapy and new triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Time Factors | 1997 |
Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child, Preschool; Drug Therapy, Combination; Gastric Mucosa; Gastritis, Hypertrophic; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole; Penicillins; Protein-Losing Enteropathies | 1997 |
Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole | 1997 |
Gastric metaplasia and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Duodenal Ulcer; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Omeprazole; Penicillins; Stomach; Treatment Outcome | 1997 |
Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Anti-Bacterial Agents; Anti-Ulcer Agents; Biomarkers; Biopsy; Chronic Disease; Clarithromycin; Duodenal Ulcer; Female; Follow-Up Studies; Gastric Juice; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Interleukin-8; Lactoferrin; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Pyloric Antrum | 1997 |
Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline; Tinidazole | 1996 |
Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Colony Count, Microbial; Drug Resistance, Microbial; Drug Synergism; Helicobacter Infections; Helicobacter pylori; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Penicillins | 1997 |
One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Lansoprazole; Male; Metronidazole; Omeprazole; Peptic Ulcer; Time Factors | 1998 |
Effect of metronidazole resistance on bacterial eradication of Helicobacter pylori in infected children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Child; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole; Prospective Studies; Spiramycin | 1998 |
Four-day quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Tetracycline | 1997 |
Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Proton Pump Inhibitors | 2000 |
Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Salicylates; Treatment Outcome; United States | 2000 |
Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Non-Hodgkin; Male; Metronidazole; Middle Aged; Omeprazole; Reverse Transcriptase Polymerase Chain Reaction; Stomach; Stomach Neoplasms | 2000 |
Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Creatinine; Female; Helicobacter Infections; Helicobacter pylori; Humans; Kidney; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Ranitidine | 2000 |
Iron-deficiency anemia associated with Helicobacter pylori gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Endoscopy, Gastrointestinal; Feces; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Iron; Lansoprazole; Male; Metronidazole; Omeprazole; Stomach; Urea | 2000 |
Endoscopic characteristics of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B-Lymphocytes; Base Sequence; Biopsy; Clone Cells; Data Interpretation, Statistical; DNA, Complementary; DNA, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell, Marginal Zone; Male; Metronidazole; Middle Aged; Molecular Sequence Data; Omeprazole; Penicillins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Time Factors | 2000 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Rabeprazole; Recurrence; Retrospective Studies; Treatment Failure | 2001 |
Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies | 2002 |
The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Combinations; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Serologic Tests | 2002 |
[Acquisition of secondary resistance after failure of a first treatment of Helicobacter pylori infection in children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Clarithromycin; Data Interpretation, Statistical; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Lansoprazole; Male; Metronidazole; Omeprazole; Penicillin Resistance; Penicillins; Retrospective Studies | 2002 |
Pseudomembranous colitis requiring surgical intervention following triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Clarithromycin; Drug Therapy, Combination; Enterocolitis, Pseudomembranous; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Omeprazole | 2002 |
Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Cicatrix; Convalescence; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Female; Follow-Up Studies; Gastric Acid; Gastric Mucosa; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Mucus; Omeprazole; Severity of Illness Index | 2003 |
Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Proton Pump Inhibitors | 2004 |
Results of triple eradication therapy in Japanese children: a retrospective multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Child; Child, Preschool; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Humans; Infant; Lansoprazole; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Retrospective Studies; Sulfoxides | 2004 |
Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Proton Pump Inhibitors; Retreatment; Time Factors | 2004 |
Some fibrocystic breast change may be caused by sexually transmitted H. pylori during oral nipple contact: supporting literature and case report of resolution after gut H. pylori eradication treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Clarithromycin; Female; Fibrocystic Breast Disease; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Models, Biological; Nipples; Serologic Tests; Time Factors; Treatment Outcome; Ultrasonography | 2007 |
Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome | 2007 |
The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Antibodies, Bacterial; Biopsy; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Japan; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Stomach; Stomach Neoplasms; Treatment Outcome | 2008 |
Ten-day sequential therapy of Helicobacter pylori infection in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Patient Compliance; Probability; Prospective Studies; Risk Assessment; Severity of Illness Index; Thailand; Time Factors; Treatment Outcome; Young Adult | 2010 |
Development of corpus atrophic gastritis may be associated with Helicobacter pylori-related idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastritis, Atrophic; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Pepsinogens; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Treatment Outcome | 2011 |
Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Metronidazole; Middle Aged; Pharmacogenetics; Proton Pump Inhibitors; Rabeprazole; Young Adult | 2011 |
Mass eradication of Helicobacter pylori: feasible and advisable?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Generic; Feasibility Studies; Female; Health Policy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Latin America; Male; Metronidazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2011 |
Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastric Acidity Determination; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Lansoprazole; Male; Metronidazole; Middle Aged; Peptic Ulcer; Pilot Projects; Prospective Studies; Proton Pump Inhibitors; Surveys and Questionnaires; Treatment Outcome | 2013 |
Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Retrospective Studies; Tokyo; Young Adult | 2013 |
What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Breath Tests; Case-Control Studies; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Organometallic Compounds; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Stomach; Tetracycline; Treatment Outcome; Urea; Young Adult | 2013 |
Black tongue due to lansoprazole plus metronidazole.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Tongue; Tongue, Hairy | 2014 |
[Ten day concomitant therapy is superior to ten day sequential therapy for Helicobacter pylori eradication].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Logistic Models; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Treatment Outcome | 2014 |
Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Otitis Media with Effusion; Proton Pump Inhibitors | 2016 |
Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Breath Tests; Clarithromycin; Cohort Studies; Female; Follow-Up Studies; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Incidence; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Proportional Hazards Models; Proton Pump Inhibitors; Pyloric Antrum; Retrospective Studies; Risk Factors; Stomach; Stomach Neoplasms | 2016 |
Authors' reply.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Otitis Media with Effusion; Proton Pump Inhibitors | 2016 |
An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Retrospective Studies | 2016 |
Helicobacter pylori eradication may successfully treat primary cutaneous follicle center lymphoma.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Doxycycline; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell; Metronidazole; Middle Aged; Organometallic Compounds; Rabeprazole; Salicylates | 2018 |
Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Female; Follow-Up Studies; Gastric Mucosa; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metaplasia; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Sex Factors; Young Adult | 2021 |
RP-HPLC-DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin, and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Naproxen; Omeprazole; Research Design; Tinidazole | 2022 |